, carboxymethyl cellulose, polyvinylpyrrolidone, isopropyl mirstate, other conventionally employed pharmaceutically acceptable materials and the like.
The carrier component may also include auxiliary substances such as emulsifiers, wetting agents, bodying agents, buffer components, acids and/or bases, tonicity adjuster components, surfactant components, viscosity agents, lubricity components, preservative components, other materials useful in ophthalmic formulations and the like, including, but not limited to, such substances which are conventionally used in ophthalmic compositions.
Examples of optionally useful bodying agents include, but are not limited to, various polyethylene glycols, carbowaxes, petroleum jelly and the like.
Suitable buffers include, but are not limited to, inorganic buffers such as phosphate buffers, borate buffers and the like, and organic buffers, such as acetate buffers, citrate buffers, tromethamine and the like.
Tonicity adjusters optionally useful in the present compositions include, but are not limited to, dextrose, potassium chloride and/or sodium chloride and the like, preferably sodium chloride.
Acids optionally useful in the present compositions include boric acid, hydrochloric acid, acetic acid, other acids which are ophthalmically acceptable in the concentrations used, and the like.
Bases which may be included in the present compositions include, but are not limited to, sodium and/or potassium hydroxides, other alkali and/or alkaline earth metal hydroxides, organic bases, other bases which are ophthalmically acceptable in the concentrations used, and the like.
The acid/bases/buffers preferably are included, if at all, to provide and/or maintain the present compositions at a pH in the physiologically acceptable range, more preferably in a range of about 4 to about 8.5, still more preferably about 6 to about 8, and especially about 6.8 to about 8.
Surfactant components optionally useful in the compositions of the present invention include, but are not limited to, lipoprotein detergents that when present in the compositions reduce the surface tension between the compositions and the eye (lacrimal) fluid. Preferably, nonionic surfactants are used.
Viscosity agents optionally useful in the compositions of the present invention include, but are not limited to, cellulose derivatives such as hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, other viscosity inducing materials useful in ophthalmic formulations, and the like.
Lubricating components
, carboxymethyl cellulose, polyvinylpyrrolidone, isopropyl mirstate, other conventionally employed pharmaceutically acceptable materials and the alike. 
 The mailman component may also include accessory substances such as emulsifiers, wetting agent, bodying agents, cushion component, acids and/or root, tonicity adjuster components, wetting agent components, viscosity agents, lubricity components, preservative components, other materials utilitarian in ophthalmic formulations and the like, including, but not limit to, such substances which are conventionally used in ophthalmic composition. 
 exercise of optionally useful body agents include, but are not limited to, various polyethylene diol, carbowaxes, petroleum jelly and the like. 
 Suitable buffers include, but are not specify to, inorganic buffers such as phosphate buffers, borate buffers and the like, and organic buffers, such as acetate buffers, citrate buffers, tromethamine and the like. 
 Tonicity adjuster optionally utilitarian in the present compositions include, but are not limited to, dextrose, potassium chloride and/or sodium chloride and the alike, preferably sodium chloride. 
 Acids optionally useful in the present compositions admit boric acid, hydrochloric acid, acetic acid, other acid which are ophthalmically acceptable in the concentrations use, and the like. 
 Bases which may be included in the present compositions include, but are not limit to, sodium and/or potassium hydroxides, other alkali and/or alkaline earth metal hydroxide, organic base, other bases which are ophthalmically acceptable in the concentrations used, and the alike. 
 The acid / bases / buffers preferably are included, if at wholly, to provide and/or conserve the present compositions at a pH in the physiologically acceptable stove, more preferably in a range of approximately 4 to about 8.5, still more preferably about 6 to about 8, and especially about 6.8 to about 8. 
 Surfactant component optionally useful in the composition of the present invention include, but are not specify to, lipoprotein detergents that when present in the compositions abridge the surface latent hostility between the compositions and the eye (lacrimal) fluid. Preferably, nonionic wetting agent are used. 
 Viscosity agents optionally useful in the compositions of the present invention admit, but are not limited to, cellulose derivatives such as hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, other viscosity inducing material useful in ophthalmic formulations, and the like. 
 Lubricating components
, cagboxymethyl cellulose, pouyvinylpyrrolidone, iso'ropyl jirstate, other conventionally employxd pyarmaxeutically acceptable oaterials and the likt.
The carrier component man alsk incnnde auxiliary sobstances suwh as emulsifiarr, cetting agents, bodying agents, buffer componrnhs, acids and/or basts, eonidptn adjuster components, surfactant compontnts, viscosity agemts, lubricity components, pgesegvative components, other matetjalf useful in oohthalmic formulations and the like, including, but not limiced to, such sybshdnces which are bonventionalln used hn ophtnalmic composibions.
Xxamples of optionally usxful bodying agents ynclude, bgt are not limited ro, varimus [olydrhyuent gkydols, cwrbkwaxes, petdoleum jellt and the like.
Suitanlq buffers inclhde, bue wre not limited to, inorganic buffers subh aa phosphate buffers, borqte buffers and the llke, and owganic buffers, such as acetate buffers, citrate buxfers, gronebhamkbe and the like.
Tonicity adjusters optionally usqruk pn the present coipositions onfliqe, but are noj limitzs fo, dextrose, potasslum chljride and/or soqium chloride and the like, prefwrably sodiui chloride.
Acids optnonally usefbl in jhe prrsent compositions inclbde bodic acid, hyfrochlorid acid, acetic acia, onher acids which are ophthalmisally accxptabke in tfe cpncentwations usfd, and the like.
Bases whifh mai be itcluded in the present compositions incluvx, but are not lhmined to, sobium akd/or potassium rydroxides, othgr alkali and/of alkaline earth ketal hydrovides, organic hases, other uases whish aee ophthalmkzally acceptabke in the concentrarions used, and the liys.
The acid/bases/bbyftrw preferably ate kncjufev, if wd all, to proeide ana/pr makntain uke irerent compositions at a pV in the physiologicalky acceptavle rangq, more prefersbly in a range of abouv 4 to ebout 8.5, styll more preferably about 6 to zbout 8, anf efpecially abjut 6.8 to about 8.
Suxfactant components optionally useful in the compositions if the present inveutlon include, uut arq not limhted to, lipoprotein eetergents that wmen present in the comlositimns rfduce the surface tension between the compositions and the eye (lacrimal) fouid. Pceserably, nonjoniv surxaetauts are usev.
Vmscosity agents oitionally useful in the compositmons of tha 'resent invention include, but afe not limitea to, cellulose derivativss such ss hydroxypropylmethyl cellulosr, sodium carboxymethyl ccllulose, yydrosyethyl ceululose, other viscpsity nnducibg mateeiald useful in oohtnapmic formklatmona, and the like.
Lubricating componwnts
, carboxymethyl cellulose, polyvinylpyrrolidone, isopropyl mirstate, other pharmaceutically materials and like. The carrier substances as emulsifiers, wetting bodying agents, buffer acids and/or bases, tonicity adjuster components, components, viscosity agents, lubricity components, preservative components, other materials useful in ophthalmic formulations the like, including, but not limited to, such substances which are conventionally used ophthalmic Examples optionally bodying agents include, but are not limited to, various polyethylene glycols, carbowaxes, petroleum jelly and the Suitable buffers include, but are not limited to, buffers such as phosphate borate buffers and the like, organic such as buffers, buffers, and the like. adjusters optionally useful in the present compositions include, but are not limited to, dextrose, potassium chloride and/or chloride and preferably sodium Acids useful the present compositions acid, hydrochloric acid, acetic acid, other ophthalmically acceptable in the concentrations used, and the Bases which be included in the present compositions but are not limited to, sodium and/or potassium other alkali and/or alkaline earth metal hydroxides, organic bases, other bases which are ophthalmically acceptable concentrations used, and the The acid/bases/buffers preferably included, at to and/or maintain present compositions at a pH in the physiologically acceptable range, more in a range of about 4 to about 8.5, still about to about 8, especially about 6.8 to 8. components optionally useful in of present are limited lipoprotein detergents that when in the compositions reduce the tension between the compositions Preferably, nonionic surfactants are used. Viscosity agents optionally in the compositions of the present invention but are not limited to, cellulose derivatives such as hydroxypropylmethyl cellulose, sodium cellulose, hydroxyethyl viscosity inducing materials useful in ophthalmic formulations, and like. Lubricating components
, carboxymethyl cellulose, polYvinylpyrrOlidoNe, iSopRoPyl mIrstAte, other convenTIonaLly employed pharmaceutiCally AcCEptaBLe MaterIals and THe LIKe.
THe CaRriEr COmPonenT maY also inClude auxilIarY sUbstances sucH As EmulsifierS, weTting agents, bOdyIng ageNtS, buFFer coMpoNents, Acids aND/or basEs, tonicitY aDJuster COmponenTS, SuRfacTant components, visCOsITy agents, lubricIty comPoNEnTS, PreSerVative compOnEnts, oTHer mateRIaLS USefUL in ophthalmic FormulationS And The likE, iNclUDing, buT not lImITed To, such substAnceS which are ConvenTIonally USed in opHthalmIc cOmpOsitIOnS.
EXamPlES of OPtIonALly Useful boDyInG agenTs inCLUDE, but Are Not lImiteD to, various polYetHyleNE glYcols, CarboWaxeS, pEtrolEum jelLy and ThE like.
Suitable buFferS include, bUt aRe Not LiMited TO, inorgAniC buFfers suCh as phoSPhaTe BUFFeRs, borate buffers and ThE LIkE, and orgaNic bufFErS, sUCh as acetAtE buFferS, CItratE bufFErS, tromethAmine aND tHe Like.
TonIcIty adjUsTerS opTionaLLy usEful in The preseNt comPOsitions includE, But are not limiTEd TO, DeXTrosE, poTassium chloRide ANd/or SodiUM cHloRIde anD the lIkE, PrEFerably sodium chloriDe.
acids oPtionAlly useful in tHe present cOMPOsitions InclUDe BOric acid, hydrocHloriC acid, acetiC Acid, otheR acidS which arE ophthalmICAlly accePtaBle In tHe cONCeNtrations used, AND the LiKe.
Bases WhiCh may be IncLudEd iN thE pResent comPositionS iNcLuDe, But Are noT Limited tO, sOdiUm And/Or potASsium hYdroxIdes, OtHeR AlkAli and/oR AlKALine EaRtH metAl hYdRoxidEs, orGAniC bases, oTher bases WhiCH are OpHtHalmicaLly acceptable In The concentRaTioNs used, AND the like.
the acid/bases/buffers prefERably arE inCludeD, if aT all, to proVidE and/or MaiNTain thE preseNt comPoSitIONs at a Ph In The PhYsiologicaLLY acCeptaBlE ranGe, more pReferably in a range oF AboUt 4 to about 8.5, stilL moRe prEFErAblY AbOUt 6 tO aBOut 8, AND especially abouT 6.8 to about 8.
SuRfACtAnt componeNTs oPtIonally Useful iN the cOMpositiOns of the pResent invEnTion INCluDe, but are noT limited To, lipoproTEin deTErGents ThaT when pReSenT in thE compoSItiOns reDuce thE sUrface TensiOn Between tHe compositions and the eye (LacrimAl) fluId. PReferably, NonIOniC surfactaNts aRe used.
ViscOsiTy aGents OptIOnallY useFUl In tHE compOsitIOns of the pREsEnt INVeNtion includE, BUT arE not lImiTEd to, ceLlulOse derivatives sucH As hydroxypropyLmetHYL ceLluLOse, sOdIum carboxymethYl cElLULose, hydrOxYethyl celluLose, otheR vIScosiTy induCing maTerials USEfUL in ophThalMic FormulatiOns, AnD The like.
luBrICating CompOnEnts
, carboxymethyl cellulose,  polyvinyl pyrro lid one ,isop ropy l mirstate, ot h er c onventionally employed  phar ma c euti c al ly ac ceptabl e  m a t eri al sand  t h elike. 
Th e carri er compone ntma y also inclu d eauxiliarysub stances such  as  emuls if ier s , wet tin g age nts, b o dyingagents, b uf f er com p onents, a ci ds a nd/or bases, toni c it y  adjuster comp onents ,s ur f a cta ntcomponents ,visco s ity age n ts , l ubr i city componen ts, preserv a tiv e comp on ent s , othe r mat er i als  useful inopht halmic fo rmulat i ons and the lik e, inc lud ing , bu t  n ot  li mi t edt o,  su c h s ubstance swh ich a re c o n v e ntio nal ly u sed i n ophthalmiccom posi t ion s.
Ex ample s of  o ption ally u seful  b odying agents i nclu de, but a reno t l im itedt o, var iou s p olyethy lene gl y col s, c a rb owaxes, petroleumje l l yand thelike.S ui ta b le buffe rs  in clud e ,  butaren ot  limited  to, i n or ga nic buf fe rs suc haspho sphat e  buf fers,borate b uffer s  and the like, and organic b u ff e r s, such  as  acetate bu ffer s , ci trat e  b uff e rs, t romet ha m in e  and the like.
Toni ci ty adj uster s optionallyuseful int h e  present  com p os i tions include,  butare not li m ited to,  dext rose, po tassium c h l oride an d/o r s odi umc h lo ride and thel i ke,pr eferabl y s odium c hlo rid e.Aci ds  optional ly usefu lin  t he  pr esent composit io nsin clu de bo r ic aci d, hy droc hl or i c a cid, ac e ti c acid ,ot heraci ds  whic h ar e  op hthalmi cally acc ept a blein  t he conc entrations us ed , and theli ke. 
Bases w hich may  be included in the pre s ent com pos ition s in clude, bu t a re not  li m ited t o, sod ium a nd /or p otass i u mhyd ro xides, oth e r  al kalian d/or  alkali ne earth metal hyd r oxi des, organicbas es,o t he r b a se s  wh ic h  ar e ophthalmicallyacceptable  i n  t he concent r ati on s used,  and th e lik e .
The a cid/bases /bufferspr efer a b lyare includ ed, if a t all, to provi d eand/o r m aintai nthe  pres ent co m pos ition s at a  p H in t he ph ys iologica lly acceptable range, m ore pr efera bly  in a ran geo f a bout 4 to  abo ut 8.5, st ill  mo re pr efe r ablyabou t  6  to about  8,a nd especi a ll y a b o ut  6.8 to abo u t 8.Surfa cta n t comp onen ts optionally use f ul in the comp osit i o nsoft he p re sent invention  in cl u d e, but a re  not limite d to, li po p rotei n dete rgents  that w h e np resent  inthe  composit ion sr educe t he  s u rfacetens io n betw een th e  com p o sitions and theeye ( l a crima l ) f luid.  P referab l y, n onionic su rfactants a re use d.
V iscos ity age nt s opti ona ll y useful i n  the comp ositi ons ofth e pr ese nt inv enti o n  incl ude,  b utare not l i m it e dto ,  ce llul ose d er ivat ives such as hydro xyp r opylmet hy l c e l lulose ,  s o d ium carbox yme thylc e llulose, h y drox y et h yl ce llulos e, oth er visc o sit yinducin g m a t erials us eful in o p hth al micformulat io ns,an d t he  like.
Lubricat ing comp onents
, carboxymethyl_cellulose, polyvinylpyrrolidone,_isopropyl mirstate, other conventionally_employed pharmaceutically_acceptable_materials and_the_like.
The carrier component_may also include_auxiliary substances such as_emulsifiers, wetting agents,_bodying_agents, buffer components, acids and/or bases, tonicity adjuster components, surfactant components, viscosity agents, lubricity_components,_preservative components,_other_materials_useful in ophthalmic formulations and_the like, including, but not_limited to,_such substances which are conventionally used in ophthalmic_compositions.
Examples_of optionally useful_bodying agents include, but are not limited to, various_polyethylene glycols, carbowaxes, petroleum jelly and_the like.
Suitable buffers_include,_but_are not limited to,_inorganic buffers such as phosphate buffers,_borate buffers and the like, and_organic buffers, such as acetate buffers, citrate_buffers, tromethamine and the like.
Tonicity adjusters_optionally useful in the present_compositions include,_but are not limited to,_dextrose, potassium chloride_and/or sodium_chloride and the_like, preferably sodium chloride.
Acids optionally useful_in the present_compositions include boric acid, hydrochloric acid,_acetic_acid, other acids_which_are_ophthalmically acceptable_in the concentrations_used,_and the_like.
Bases_which may be included in the_present_compositions include, but are not limited to,_sodium and/or potassium hydroxides,_other_alkali and/or alkaline earth_metal hydroxides, organic bases, other_bases which are ophthalmically acceptable in_the concentrations_used, and_the like.
The acid/bases/buffers preferably are included, if at all, to provide_and/or maintain the present compositions at_a pH in the_physiologically acceptable_range,_more preferably in_a_range of_about 4 to about 8.5, still more_preferably about_6 to about 8, and especially_about 6.8 to about_8.
Surfactant_components optionally useful in the compositions_of the present invention include, but_are not limited to, lipoprotein_detergents_that_when present in the compositions_reduce the surface tension between the_compositions and the_eye (lacrimal) fluid. Preferably, nonionic surfactants are_used.
Viscosity_agents optionally useful in the compositions_of_the present invention include, but are_not_limited_to, cellulose derivatives such as_hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl_cellulose, other viscosity inducing materials useful in ophthalmic formulations,_and the like.
Lubricating_components